Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. April 2026 09:59 ET | Quelle: GeneProof part of NuvinkaDX

GeneProof Announces CMV IVDR Launch on the myCROBE™ Fully Automated System for Transplant Care

Brno, Czechia, April 02, 2026 (GLOBE NEWSWIRE) -- GeneProof, a molecular diagnostics manufacturer and part of NuvinkaDx, announced several significant product and regulatory milestones. The...
02. April 2026 09:06 ET | Quelle: BCC Research LLC

Global Flexible PCB Market to Nearly Double, Reaching $41.7 Billion by 2030 on Surging Demand from Consumer Electronics, EVs and 5G Infrastructure

According to BCC Research, growing demand for compact, lightweight, and high-performance electronic devices is driving strong growth in the FPCB market.
02. April 2026 08:30 ET | Quelle: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

If approved, UX111 will be the first approved therapy for the treatment of Sanfilippo syndrome Type A, a rare disease affecting young children that leads to progressive, irreversible neurodegeneration...
02. April 2026 08:00 ET | Quelle: Revolution Medicines, Inc.

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer

REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today...
02. April 2026 08:00 ET | Quelle: Bionano Genomics

Bionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study in the American Journal of Hematology demonstrating that optical genome...
02. April 2026 08:00 ET | Quelle: Royal Philips

MDIC appoints Philips Chief Medical Officer Carla Goulart Peron as new board member

April 2, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Carla Goulart Peron, MD, Chief Medical Officer at Philips,...
02. April 2026 07:30 ET | Quelle: Plus Therapeutics Inc.

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), today announces a new payer...
02. April 2026 07:30 ET | Quelle: MiNK Therapeutics

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell...
02. April 2026 07:01 ET | Quelle: Adagene Inc.

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide...
02. April 2026 07:00 ET | Quelle: Neutrolis, Inc.

Neutrolis Announces Positive First-in-Human Phase 1a Results from LIBERATE-I Trial of NTR-1011, a First-in-Class DNASE1L3 Fusion Protein

NTR-1011 demonstrated a favorable safety, tolerability, and immunogenicity profile across multiple dose levels of intravenous (IV) and subcutaneous (SC) administrationsNTR-1011 displayed a predictable...

Vorherige Seite

Nächste Seite